Abstract | BACKGROUND: METHODS: We randomly assigned 614 patients younger than 65 years of age who had nonprogressive disease after first-line transplantation to maintenance treatment with either lenalidomide (10 mg per day for the first 3 months, increased to 15 mg if tolerated) or placebo until relapse. The primary end point was progression-free survival. RESULTS:
Lenalidomide maintenance therapy improved median progression-free survival (41 months, vs. 23 months with placebo; hazard ratio, 0.50; P<0.001). This benefit was observed across all patient subgroups, including those based on the β(2)-microglobulin level, cytogenetic profile, and response after transplantation. With a median follow-up period of 45 months, more than 70% of patients in both groups were alive at 4 years. The rates of grade 3 or 4 peripheral neuropathy were similar in the two groups. The incidence of second primary cancers was 3.1 per 100 patient-years in the lenalidomide group versus 1.2 per 100 patient-years in the placebo group (P=0.002). Median event-free survival (with events that included second primary cancers) was significantly improved with lenalidomide (40 months, vs. 23 months with placebo; P<0.001). CONCLUSIONS:
Lenalidomide maintenance after transplantation significantly prolonged progression-free and event-free survival among patients with multiple myeloma. Four years after randomization, overall survival was similar in the two study groups. (Funded by the Programme Hospitalier de Recherche Clinique and others; ClinicalTrials.gov number, NCT00430365.).
|
Authors | Michel Attal, Valerie Lauwers-Cances, Gerald Marit, Denis Caillot, Philippe Moreau, Thierry Facon, Anne Marie Stoppa, Cyrille Hulin, Lofti Benboubker, Laurent Garderet, Olivier Decaux, Serge Leyvraz, Marie-Christiane Vekemans, Laurent Voillat, Mauricette Michallet, Brigitte Pegourie, Charles Dumontet, Murielle Roussel, Xavier Leleu, Claire Mathiot, Catherine Payen, Hervé Avet-Loiseau, Jean-Luc Harousseau, IFM Investigators |
Journal | The New England journal of medicine
(N Engl J Med)
Vol. 366
Issue 19
Pg. 1782-91
(May 10 2012)
ISSN: 1533-4406 [Electronic] United States |
PMID | 22571202
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Thalidomide
- Lenalidomide
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(adverse effects, therapeutic use)
- Disease-Free Survival
- Double-Blind Method
- Female
- Follow-Up Studies
- Humans
- Kaplan-Meier Estimate
- Lenalidomide
- Maintenance Chemotherapy
- Male
- Middle Aged
- Multiple Myeloma
(drug therapy, mortality)
- Neoplasms, Second Primary
(epidemiology)
- Stem Cell Transplantation
- Thalidomide
(adverse effects, analogs & derivatives, therapeutic use)
- Young Adult
|